Last reviewed · How we verify
Combigan Eye drops
At a glance
| Generic name | Combigan Eye drops |
|---|---|
| Also known as | Brimonidine tartrate 2.0mg, Timolol maleate 6.8mg(with preservative) |
| Sponsor | CHA University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of Efficacy and Ocular Surface Assessment Between BRIDIN-plus and Combigan in Glaucoma or Ocular Hypertensive (PHASE4)
- BREMEN Eye Drops Versus Combigan for Open-angle Glaucoma or Intraocular Hypertension (PHASE3)
- Prophylaxis for Anti-VEGF-induced IOP Elevation (NA)
- Effect of Lowering IOP in Glaucoma Suspects With HM (NA)
- Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan® (PHASE4)
- Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow (PHASE4)
- Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects (PHASE4)
- Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Combigan Eye drops CI brief — competitive landscape report
- Combigan Eye drops updates RSS · CI watch RSS
- CHA University portfolio CI